1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy
    Meeting Abstract

    Khan, S.; Lutzky, J.; Shoushtari, A. N.; Jeter, J. M.; Chiuzan, C.; Sender, N.; Blumberg, L. E.; Nesson, A.; Singh-Kandah, S. V.; Hernandez, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Ixazomib-dexamethasone (Ixa-Dex) vs physician's choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial
    Meeting Abstract

    Kastritis, E.; Dispenzieri, A.; Wechalekar, A. D.; Schonland, S. O.; Kim, K.; Sanchorawala, V.; Landau, H. J.; Kwok, F.; Suzuki, K.; Comenzo, R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia
    Meeting Abstract

    Januzzi, J. L.; Garasic, J.; Kasner, S.; McDonald, V.; Petrie, M. C.; Seltzer, J.; Mauro, M. J.; Croce, K.; Berman, E.; Deininger, M. W. N.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance)
    Meeting Abstract

    Hertz, D. L.; Larson, N. B.; Pierpont, T.; Bartlett, N. L.; Zelenetz, A. D.; Wilson, W. H.; Leonard, J. P.; Jung, S. H.; Riska, S. M.; Richards, K. L.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Association of tumor mutations with arterial thromboembolism risk in patients with solid cancer
    Meeting Abstract

    Ho, K. W.; Gupta, D.; Bolton, K. L.; Dunbar, A. J.; Willeit, P.; Soff, G. A.; Jee, J.; Zehir, A.; Bryce, Y.; Sidlow, R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • The nature and management of acquired resistance to PD1-based therapy in melanoma
    Meeting Abstract

    Hepner, A.; Versluis, J. M.; Gerard, C. L.; Brown, L. J.; Wallace, R.; Bhave, P.; Jansen, Y.; Klein, O.; Warner, A. B.; Mangana, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM)
    Meeting Abstract

    Hari, P.; Pasquini, M. C.; Stadtmauer, E. A.; Fraser, R.; Fei, M.; Devine, S. M.; Efebera, Y. A.; Geller, N.; Horowitz, M. M.; Koreth, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab
    Meeting Abstract

    Ghione, P.; Joffe, E.; De Paola, N.; Mainardi, T.; Noor, S. J.; Bobillo, S.; Myskowski, P. L.; Palomba, M. L.; Moskowitz, A. J.; Mato, A. R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML)
    Meeting Abstract

    Dinardo, C. D.; Schuh, A. C.; Stein, E. M.; Montesinos, P.; Wei, A.; De Botton, S.; Zeidan, A. M.; Fathi, A. T.; Quek, L.; Kantarjian, H. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML)
    Meeting Abstract

    Dinardo, C. D.; Stein, E.; Pigneux, A.; Altman, J. K.; Collins, R.; Erba, H. P.; Watts, J. M.; Uy, G. L.; Kapsalis, S. M.; Liu, H.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save